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Abstract
Background: Chronic kidney disease (CKD) is an emerging worldwide problem. The lack of attention paid to kidney
disease is well known and has been described in previous publications. However, little is known about the magnitude of
the problem in highly specialized hospitals where serum creatinine values are used to estimate GFR values.
Methods: We performed a cross-sectional evaluation of hospitalized adult patients who were admitted to the medical
or surgical department of Santa Maria della Misericordia Hospital in 2007. Information regarding admissions was derived
from a database. Our goal was to assess the prevalence of CKD (defined as an estimated glomerular filtration rate [eGFR]
< 60 mL/min/1.73 m2) and detection of CKD using diagnostic codes (Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM]). To reduce the impact of acute renal failure on the study, the last eGFR obtained during
hospitalization was the value used for analysis, and intensive care and nephrology unit admissions were excluded. We
also excluded patients who had ICD-9-CM codes for renal replacement therapy, acute renal failure, and contrast
administration listed as discharge diagnoses.
Results: Of the 18,412 patients included in the study, 4,748 (25.8%) had reduced eGFRs, falling into the category of
Kidney Disease Outcomes Quality Initiative (KDOQI) stage 3 (or higher) CKD. However, the diagnosis of CKD was
only reported in 19% of these patients (904/4,748). It is therefore evident that there was a "gray area" corresponding to
stage 3 CKD (eGFR 30-59 ml/min), in which most CKD diagnoses are missed. The ICD-9 code sensitivity for detecting
CKD was significantly higher in patients with diabetes, hypertension, and cardiovascular disease (26.8%, 22.2%, and 23.7%,
respectively) than in subjects without diabetes, hypertension, or cardiovascular disease (p < 0.001), but these values are
low when the widely described relationship between such comorbidities and CKD is considered.
Conclusion: Although CKD was common in this patient population at a large inpatient regional hospital, the low rates
of CKD detection emphasize the primary role nephrologists must play in continued medical education, and the need for
ongoing efforts to train physicians (particularly primary care providers) regarding eGFR interpretation and systematic
screening for CKD in high-risk patients (i.e., the elderly, diabetics, hypertensives, and patients with CV disease).
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Background
Chronic kidney disease (CKD) represents a serious public
health problem, as CKD rates are constantly rising all over
the world [1-4]. Large population-based studies [2,5] have
shown that 1 of every 10 adults is affected by CKD in the
United States. This disease is defined by the National Kid-
ney Foundation Kidney Disease Outcomes Quality Initia-
tive (NKF KDOQI ™) as either kidney damage or decrease
in glomerular filtration rate (GFR) persisting for at least
three months, and is classified in five stages of increasing
severity (KDOQI stages) [6]. CKD can be easily detected
with simple biochemical tests, including the estimated
glomerular filtration rate, which is calculated from serum
creatinine values (eGFR) [7,8]. Identifying subjects with
CKD (i.e., those with an eGFR <60 ml/min/1.73 m2, or
KDOQI stage ≥ 3) is extremely important for two reasons.
The first is that timely intervention can slow disease pro-
gression, thereby increasing the period of time that
patients are free from dialysis, and reducing both risks for
patients and costs to national health care systems[9,10].
The second is that patients with stage 4 or 5 CKD have a
2- to 4-fold greater risk of developing cardiovascular dis-
ease than age-matched subjects with normal kidney func-
tion [1,11-13], and it has been shown that early
identification of CKD may reduce cardiovascular disease
rates in these patients [14,15].
While the primary prevention of CKD is somewhat diffi-
cult, secondary prevention should theoretically be easier
because it is related to numerous risk factors that are
present in a large proportion of the population; these
include diabetes, high blood pressure, cardiovascular dis-
ease, and other lifestyle factors that are relatively easy to
identify. Secondary prevention, however, requires a
timely diagnosis of CKD. Indeed, several previous studies
[7,8] have suggested that an early diagnosis of CKD can be
obtained from patients' eGFR, calculated using the Modi-
fication of Diet in Renal Disease (MDRD) formula [16-
18].
The existence of tests for detecting a given disease does not
mean that the disease will necessarily be identified. Ryan
[19] demonstrated that as many as three-quarters of
patients affected by CKD who were under the care of gen-
eral practitioners in Great Britain had not been diagnosed.
The situation in Italy is similar. One large Italian study
demonstrated that only one of seven patients affected by
CKD and under the care of general practitioners was cor-
rectly identified [20].
In order to simplify the identification of CKD and attract
attention to this problem, many laboratories are now
equipped with software that automatically calculates
patients' eGFR using standardized formulas. Our hospi-
tal's laboratory (Santa Maria della Misericordia Hospital,
Perugia, Italy) reports eGFR using the MDRD formula for
all patients who have serum creatinine testing performed.
The two values are listed one after the other in order to
allow physicians to recognize immediately the association
between the serum creatinine value and renal function.
However, the extent to which this measure has succeeded
at improving the rate of diagnosis of CKD remains
unknown.
KDOQI guidelines define CKD as a decrease in GFR for a
duration of at least three months. However, it is difficult
to obtain a long-term follow-up for a large number of hos-
pitalized patients. Therefore, despite the fact that a single
evaluation of eGFR may overestimate the number of
patients with CKD, we evaluated how often hospital phy-
sicians included CKD in patients' discharge diagnoses (by
listing an ICD-9 code reflective of CKD), even for hospi-
talizations not directly related to kidney disease, when
data regarding eGFR were available during the hospitali-
zation.
Methods
Data for this cross-sectional study were obtained by ana-
lyzing the records of the centralized analysis laboratory of
Santa Maria della Misericordia Hospital in Perugia. The
computerized system uses software developed by Bayer -
SIEMENS that is based on Oracle and the LMX system. In
order to maintain the integrity of laboratory data, the sys-
tem sends the data to an external database that can be que-
ried via the internet using software developed by
TECNIDATA SrL.
Serum creatinine testing was carried out using ADVIAA
1800 (SIEMENS) equipment and was based on the reac-
tion of picric acid with creatinine in an alkaline environ-
ment, as originally described by Jaffe [21]. Calibration of
creatinine levels was performed by the SIEMENS method
using High Performance Liquid Chromatography
(HPLC). We queried the laboratory database to obtain all
laboratory results of all patients admitted to Santa Maria
della Misericordia Hospital between January 1st  and
December 31st 2007. We excluded patients admitted to
intensive care units or to the nephrology department. We
obtained a file that contained a total of 107,569 serum
creatinine values for 33,743 hospitalizations that
occurred during 2007.
For patients who had multiple creatinine values for the
same admission, we considered only the last creatinine
value (i.e., the value obtained closest to the time of dis-
charge, and therefore the value that would best approxi-
mate a patient's renal function at the time of discharge).
We also excluded 1,452 admissions of pediatric patients
(less than 15 years of age), 65 admissions for renal
replacement therapy, and 6,795 admissions in whichBMC Nephrology 2009, 10:24 http://www.biomedcentral.com/1471-2369/10/24
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diagnoses were missing or the data were incomplete. The
final file contained complete data on 25,431 hospitaliza-
tions (or discharges) of 18,412 patients. A total of 3,996
patients were admitted more than once during 2007, for a
total of 11,015 admissions (3,996 first admissions and
7,019 consecutive admissions, mean number of admis-
sions = 2.7 per patient).
For each patient included in the final analysis, we
obtained the last measured serum creatinine value before
admission and the associated eGFR, which was calculated
using the appropriate MDRD formula [eGFR = 175 ×
(sCr.-1.154 × age-0.203)]. This value is multiplied by 0.742
for females [7,8]. We also collected data regarding dis-
charge diagnoses as documented by ICD-9 codes (note
that at discharge, up to six separate diagnoses may be
listed), discharge department, and age at discharge.
Patients were classified according to Kidney Disease Out-
comes Quality Initiative (KDOQI) stages and CKD was
defined as the presence of CKD with KDOQI stage 3 or
higher (a moderate or severe reduction in GFR or kidney
failure).
We considered the ICD-9 codes listed in Table 1 to be
reflective of the presence of kidney disease when listed as
discharge diagnoses. When patients had additional ICD-9
codes for renal replacement therapy (i.e., v56A, v45B),
acute renal failure (i.e., 584.5, 584.8, 584.9), or contrast
procedures (i.e., 88.4×, 88.5×), they were excluded from
the study. We obtained the codes we used from ICD9-CM-
2002 (Italian Version), which was introduced into the
Italian coding system on January 1, 2006.
The primary analysis sought to determine the sensitivity,
specificity, positive likelihood ratio (LR), negative LR and
post-test odds of ICD-9 diagnosis codes for the detection
of chronic kidney disease. We did this in order to test the
ability of administrative databases based on ICD-9 codes
to accurately identify CKD when it is present, and in order
to verify whether reduced eGFR levels drew attention to
CKD independently from the cause of admission.
Sensitivity was defined as the proportion of patients with
CKD who were correctly identified, and specificity as the
proportion of patients without CKD who were correctly
identified based on the ICD-9 codes listed at the time of
discharge. The positive LR was calculated by dividing the
sensitivity of the assay by the false positive rate (1-specifi-
city). The negative LR was calculated by dividing the false
negative rate (1-sensitivity) of the assay by its specificity
[22]. LRs greater than 1 tell us a test result is more likely to
occur among patients with the disease than among those
without the disease; LRs less than 1 tell us a result is less
likely to occur among patients with the disease than
among patients without the disease. LRs of 10 or more
usually "rule in" disease; LRs of 0.1 or less usually "rule
out" disease. An LR of 1 is completely useless in ruling dis-
ease in or out [23]. The positive and negative LRs do not
change as the underlying probability of disease changes,
because the probability of disease is captured mostly in
the prevalence term. The main term that contains preva-
lence information is the pre-test odds, which can be calcu-
lated as:
For this reason, pre-test odds are used to "weight" the pos-
itive and negative LR. The "weighted" positive and nega-
tive LR are mathematically equivalent to the post-test
odds, that can be calculated as: Post-test odds = Pre-test
odds × Likelihood Ratio. Therefore, the post-test odds
incorporate information about the disease prevalence, the
patient pool, and specific patient risk factors (pre-test
odds), as well as information about the diagnostic test
itself (the likelihood ratio). The post-test probability can
be calculated as: Post-test probability = post-test odds/
(post-test odds + 1). A LR greater than one produces a
post-test probability which is higher than the original pre-
test probability. A LR less than one produces a post-test
probability which is lower than the original pre-test prob-
ability [24].
The inherent variation in test performance among patient
subgroups, or spectrum effect [25], was assessed by com-
paring the sensitivity and specificity values of the assay for
patients in two predetermined subgroups (e.g., age ≥ 70
years vs. < 70 years, males vs. females) using the z test.
Additionally, we explored whether changing the eGFR
threshold for CKD from the "true" value of < 60 ml/min
to < 30 ml/min (stages 4 and 5 only) or even to < 15 ml/
min (stage 5 only) was able to change ICD-9 performance.
We did so in order to determine whether physicians are
more likely to notice lower reported eGFR values when
assigning ICD-9 codes at the time of discharge. Secondary
analyses explored the correlation between multiple risk
factors (such as diabetes, hypertension, and cardiovascu-
lar disease) and the prevalence of CKD. When an ICD-9
code for diabetes mellitus was present as one of the six dis-
charge diagnoses, the patient was coded as diabetic ("1"
code). Similarly, a patient was considered hypertensive
Pre-test odds =
−
prevalence
prevalence 1
Table 1: ICD-9-CM codes for kidney disorders*
ICD-9 Code Diagnosis
585 Chronic kidney disease (CKD)
586 Renal failure, unspecified
*2002 versionBMC Nephrology 2009, 10:24 http://www.biomedcentral.com/1471-2369/10/24
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(coded as "1") when an ICD-9 code for essential hyperten-
sion was present as one of the six discharge diagnoses.
Cardiovascular disease was considered present (coded as
"1") when any of the six discharge diagnoses contained an
ICD-9 code corresponding to the following diseases: myo-
cardial infarction (including subendocardial infarction),
congestive heart failure, coronary heart disease (including
angina), or stroke. Uni- and multivariate log-binomial
regression analysis was conducted to determine the prev-
alence ratios for the outcome, CKD [26,27], using the fol-
lowing dichotomized variables: age (≥ 70 vs. < 70), sex
(male vs. female), diabetes (yes/no), hypertension (yes/
no), CV disease (yes/no), and department of admission
(medical vs. surgical). For the purposes of the primary and
secondary analyses, only the first admission was consid-
ered in order to avoid counting the same patients twice.
Finally, for each patient with repeated admissions, the
first and last admission were compared in order to assess
test-retest reliability of reported eGFR values and inter-
rater agreement of the ICD-9 diagnosis of CKD using the
κ statistic and the phi coefficient [28]. For this study, we
consider a kappa less than zero to indicate less than
chance agreement, 0.01-0.20 slight agreement beyond
chance, 0.21-0.40 fair agreement, 0.41-0.60 moderate
agreement, 0.61-0.80 substantial agreement, and 0.81-
0.99 almost perfect agreement [29]. The phi coefficient
measures the correlation between two nominal variables
and ranges from -1 to 1. This measure is similar to the cor-
relation coefficient in its interpretation [30]. Descriptive
statistics were assessed and are presented as frequencies,
means, standard deviations, and confidence intervals.
Groups were compared using the unpaired Student's t-test
or the χ2 test. For all analyses, a two-sided p-value of less
than 0.05 was considered to indicate statistical signifi-
cance. Statistical analysis was performed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA) and STATA version 10.0
(StataCorp LP, College Station, Texas, USA).
Results
The performance characteristics of ICD-9 codes for detect-
ing CKD in various subgroups of patients admitted during
2007 are reported in [additional file 1]. Only data from
the first admission were included for patients admitted
multiple times in 2007.
Of the 18,412 patients included in the analysis, 52.7%
were male. The mean age of included patients was 61.5 ±
19.8 (mean ± SD) years (range 15-99 years). Patients dis-
charged from surgical departments were younger (61.7 ±
18.8 years) than patients discharged from medical depart-
ments (66.1 ± 17.6 years). Age (≥ 70 vs. < 70 years) did
not affect test sensitivity, which was about 19% for both
age groups (p = 0.86).
Medical comorbidities such as diabetes, hypertension,
and CV disease associated with a risk of developing CKD,
were associated with a statistically significant improve-
ment in test sensitivity (26.8%, 22.2%, and 23.7% vs.
17.1%, 16.9% and 16.1% in subjects without diabetes,
hypertension or CV disease, respectively; p < 0.001).
Admission to medical departments (internal medicine
and its branches: oncology, endocrinology, gastroenterol-
ogy, geriatrics, occupational medicine, hematology, infec-
tious diseases, and cardiology) was associated with a
statistically significant improvement in test sensitivity as
compared to admission to surgical departments (general
surgery and its branches: surgical oncology, thoracic sur-
gery, digestive tract, urology, heart surgery, orthopedic
surgery, vascular surgery, ophthalmology, ear, nose, and
throat surgery, and neurosurgery) (17.4% vs. 13.0%, p =
0.001).
In male patients, the sensitivity of ICD-9 codes for detect-
ing the presence of CKD was 28.4%, as compared to 12%
in female patients (p < 0.001).
The overall sensitivity of ICD-9 codes for detecting
patients with CKD (stage 3 or higher) was low at only
19%. However, when the eGFR threshold for CKD was
lowered from the "true" value of less than 60 ml/min to
30 ml/min (stage 4 or 5 only) or even 15 ml/min (stage 5
only), a striking increase in ICD-9 sensitivity was found
(55.7% and 70.6%, respectively).
The overall prevalence of CKD was high (25.8%, 95% CI
25.1-26.4), and it was even higher in "high-risk" patients
such as diabetics (41.3%, 95% CI 39.3-43.3), hyperten-
sives (36.9%, 95% CI 35.6-38.2) and patients with CV dis-
ease (43.9%, 95% CI 42.4-45.4), as compared to lower-
risk patients (p < 0.001). The prevalence of CKD was
higher in females than in males (31.1% vs. 21%, p <
0.001), which is consistent with previous reports [31].
Table 2 shows the results of uni- and multivariate analyses
of each of the clinical variables that were included in the
study; age ≥ 70 years, female sex, and admission to medi-
cal departments as well as the presence of diabetes, hyper-
tension, and CV disease were all associated with a
statistically significant increase in the estimated preva-
lence ratios for CKD, both in the unadjusted and in the
adjusted models (p < 0.001). This relationship was partic-
ularly strong in the elderly (adjusted PR 3.41, 95% CI 3.2-
3.63, p < 0.001).
When analyzing patients with multiple admissions, the
agreement was moderate between the first and last admis-
sion in terms of CKD status as assessed by reported eGFR
(κ: 0.429, p < 0.001; phi: 0.522, p < 0.001). The inter-rater
agreement for ICD-9 diagnosis of CKD was also moderate
(κ: 0.493, p < 0.001; phi:0.497, p < 0.001). Of course,
inter-rater agreement does not necessarily imply a correctBMC Nephrology 2009, 10:24 http://www.biomedcentral.com/1471-2369/10/24
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evaluation: physicians could be using incorrect evaluation
schemes.
Finally, when all 25,431 discharges are considered, an
ICD-9 diagnosis of kidney disorder was the main diagno-
sis in 267 cases, the second diagnosis in 356 cases, the
third diagnosis in 342 cases, the fourth diagnosis in 330
cases, the fifth diagnosis in 257 cases, and the sixth diag-
nosis in 133 cases, for a total of 1,685 cases (6.6% of dis-
charges).
Table 3 lists the KDOQI stage of the 25,431 hospitaliza-
tions considered in the study. A total of 9,132 discharges
(35.9% of the total, corresponding to 4,748 patients with
CKD) had stage 3 or higher CKD, but a correct ICD-9 diag-
nosis of CKD was reported in only 1,579/9,132 (16%)
cases. On the other hand, ICD-9 diagnosis of CKD was
incorrectly reported in only 106/16,299 (0.65%) admis-
sions, with the renal function of these patients falling into
stages 1 or 2 CKD as determined by eGFR reporting.
Discussion
The prevalence of CKD is increasing worldwide due to the
aging of the general population and the increasing preva-
lence of diabetes, hypertension, and CV disease [3].
Among the 18,412 patients hospitalized during 2007, the
overall prevalence of CKD was high (about 25%). In par-
ticular, nearly half of patients older than 70 years of age
had CKD. The prevalence of CKD in patients with CV dis-
ease, diabetes and hypertension was only slightly lower
than the prevalence in older individuals (44%, 41%, and
37%, respectively). CKD has been shown to be an inde-
pendent risk factor for adverse cardiovascular events and
mortality. In fact, for each CKD patient who lives long
enough to develop end-stage renal disease requiring dial-
ysis, several patients have already had fatal or non-fatal
CV events [1,32]. Therefore, identifying patients with
CKD has become a major health issue. However, identifi-
cation of kidney disease does not often happen early in
the course of the disease, not only because it progresses
asymptomatically until kidney function is severely com-
promised, but also because the reported "normal" range
for serum creatinine values does not take into considera-
tion patients' age and anthropomorphic characteristics.
To solve this problem, a number of standardized formulas
for estimating patients' creatinine clearance [33] or
glomerular filtration rate [7,8] have been developed.
Table 2: Prevalence ratios of CKD*
Covariates PR Estimated PR
(unadjusted)
95% CI P Estimated
(adjusted)
95% CI P
Age ≥ 70 vs. age <70 4.11 3.88-4.37 <0.001 3.41 3.20-3.63 <0.001
Female vs. male 1.48 1.41-1.55 <0.001 1.45 1.39-1.51 <0.001
Diabetes vs. no diabetes 1.75 1.66-1.85 <0.001 1.21 1.16-1.27 <0.001
Hypertension vs.
no hypertension
1.72 1.64-1.80 <0.001 1.23 1.18-1.28 <0.001
CV disease vs.
no CV disease
2.14 2.04-2.24 <0.001 1.41 1.35-1.47 <0.001
Admission to medical
vs. surgical department
1.52 1.44-1.60 <0.001 1.09 1.03-1.14 0.001
*Values obtained from uni- and multivariate log-binomial regression models
PR: prevalence ratio; CI: confidence interval
Table 3: Number of admissions with or without the ICD-9 diagnosis of CKD at discharge, stratified by KDOQI stage
KDOQI
Stage
ICD-9 diagnosis 3 4 5 All admissions with KDOQI stage ≥ 3
No CKD 6,838
(90.5%)
550
(7.3%)
165
(2,2%)
7,553
CKD 793
(50.2%)
490
(31.1%)
296
(18.7%)
1,579
KDOQI: Kidney Disease Outcomes Quality InitiativeBMC Nephrology 2009, 10:24 http://www.biomedcentral.com/1471-2369/10/24
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The health information systems that are currently in place
in various health organizations [34] use the MDRD for-
mula to calculate an eGFR value for each patient who has
serum creatinine levels tested in order to overcome prob-
lems associated with the variability of "normal" creatinine
values and their interpretation by physicians.
The lack of attention paid to kidney disease by physicians
is well known from the literature. This study is the first
one to quantify this phenomenon in a highly specialized
hospital where patient eGFRs are calculated in a standard-
ized fashion each time the serum creatinine is evaluated.
Thus, all physicians who request serum creatinine values
are always informed about that patient's renal function,
and it is up to the physician to place the proper emphasis
on it.
At least theoretically, being aware of this value and cor-
rectly interpreting it should help with the diagnosis of
CKD [35], as timely identification is extremely important
for slowing progression and reducing the associated
increase in cardiovascular risk [36,37]. In sharp contrast
with this hypothesis, the present study highlights that in
80% of hospitalizations in which there was documented
evidence of renal failure by eGFR, CKD was not listed as a
final ICD-9 code diagnosis, thus underscoring the pitfalls
associated with this approach [38-40]. Notably, we found
that while only 19% of patients with stage 3 or higher
CKD (eGFR < 60 ml/min) received a correct ICD-9 diag-
nosis of kidney failure, this percentage rose to 56% in
patients with stage 4 or 5 CKD (eGFR < 30 ml/min).
Although diagnosing half of patients with advanced kid-
ney disease based on available laboratory data should not
be considered a "good" result, it is evident that ICD-9 per-
formance improved considerably in this subgroup of
patients. There may be several explanations for this. Per-
haps physicians do actually take into account lower values
of reported eGFR (i.e., values <30 ml/min) when assign-
ing ICD-9 codes at discharge, but fail to recognize moder-
ate CKD (stage 3) as a clinical problem. Alternatively, it is
possible that they use creatinine values when assigning an
ICD-9 diagnosis of CKD, because creatinine values are
usually only elevated above the "normal" range when
eGFR falls below 30 ml/min; for higher values of eGFR,
creatinine values remain "normal", and therefore an ICD-
9 diagnosis of CKD may remain overlooked. Whatever the
cause, our study highlights the presence of a "gray area",
corresponding to stage 3 CKD, in which most of the diag-
noses are missed. In particular, when considering the first
admissions of 18,412 patients admitted during 2007,
4,096 had an eGFR between 30 and 59 ml/min, but only
537 (13.1%) correctly received a diagnosis of chronic kid-
ney disease. Thus, only one in eight patients with stage 3
CKD received an ICD-9 diagnosis of kidney failure. This is
of great concern when considering the importance of early
diagnosis not only in reducing the burden of kidney dis-
ease, but also in preventing the adverse effects of inade-
quate drug dosing or inappropriate exposure to
nephrotoxic agents.
Another important point is the very low detection rate of
CKD in the elderly that we observed in this study.
Although the estimated prevalence ratio for CKD was 3.41
(3.20-3.63, p < 0.001) in patients ≥ 70 years of age as com-
pared to patients <70 years of age, the ICD-9 sensitivity for
detection of CKD was similar between the two groups
(19% vs. 19.2%, p = 0.68), indicating that physicians
failed to pay the necessary attention to renal function
when evaluating higher-risk elderly patients.
On the other hand, detection of CKD through ICD-9
codes was significantly better in patients with diabetes
mellitus, hypertension, or CV disease as compared to
patients without diabetes, hypertension, or CV disease
(sensitivity values: 26.8%, 22.2%, and 23.7%, vs. 17.1%,
16.9, and 16.1%, respectively; p < 0.001), although these
values are still low when considering the widely described
relationship between such comorbidities and CKD.
A statistically significant difference in the detection of
CKD was also evident in patients admitted in medical
departments as compared to surgical departments (17.4%
vs. 13.0%, p = 0.001). It is possible that medical special-
ists are slightly more careful about evaluating eGFR at the
time of discharge than surgical specialists. However, this
phenomenon likely only has a small amount of clinical
relevance given the magnitude of the problem.
The performance of ICD-9 codes in detecting CKD varied
significantly between females and males (sensitivity: 12%
vs. 28.4%, p < 0.001). We are unable to find any obvious
explanation for this performance variation at the present
time and are planning further analyses of our data to fur-
ther explore the spectrum effect of ICD-9 performance.
Our study has several limitations. First, the diagnosis of
chronic kidney disease was based on a single determina-
tion of serum creatinine level and eGFR [20,41] because
our database was created using administrative data about
a large number of hospitalized patients, and because
nearly every hospitalization lasted less than three months.
Consequently, we may have overestimated the number of
patients with chronic kidney disease. However, the risk of
overestimating CKD is counterbalanced by the use of a
single centralized laboratory and by the availability of
serum creatinine calibration[42,43], allowing the reduc-
tion of misclassification bias. Secondly, although eGFR
has been widely used to diagnose CKD in hospitalized
patients [44] with a wide spectrum of pathologies, includ-
ing acute coronary syndromes [45], congestive heart fail-BMC Nephrology 2009, 10:24 http://www.biomedcentral.com/1471-2369/10/24
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ure [46] and stroke [47], equations for estimated GFR
perform better for healthy, stable patients than for acutely
ill, hospitalized patients [48]. To reduce the impact of
acute renal failure on the study, the last eGFR for hospital-
ization was analyzed, intensive care and nephrology unit
admissions were excluded, and patients whose discharge
forms included ICD-9-CM code diagnoses, renal replace-
ment therapy, acute renal failure, or contrast administra-
tion were excluded from the analysis.
Conclusion
Because administrative information such as hospital dis-
charge data is often used for surveillance purposes [49],
underestimation of CKD among hospitalized patients
may lead to a further reduced awareness of kidney disease
among public health professionals, family medicine pro-
gram directors and, ultimately, among general practition-
ers. It is important to note that nephrologists are
consultants, and that they should not and cannot see all
patients in order to diagnose CKD. Thus, the responsibil-
ity for the primary diagnosis of CKD lies in the hands of
general practitioners and other specialists. However, an
analysis based on the National Health and Nutrition
Examination Surveys (NANHES III) and Medicare data-
bases showed that CKD care is suboptimal [50], and two
recent online surveys [51,52] suggest that primary care
providers [53] and internal medicine residents may be not
familiar with KDOQI guidelines. The presence of chronic
renal failure is often considered an additional piece of
information that has little effect on the general clinical
assessment of patients, as if the presence of CKD does not
modify patient prognosis and does not warrant interven-
tion.
It therefore seems that the best approach to the problem
of the under-diagnosis of CKD is to ensure that all health
care professionals, both generalists and specialists, under-
stand the importance of the early diagnosis of kidney dis-
ease. Physicians should be made especially aware that
older patients and patients with diabetes, hypertension, or
CV disease should be systematically screened for the pres-
ence of chronic kidney disease. This message could be eas-
ily transmitted through public health programs [54]. It is
hoped that ICD-9 performance in detecting CKD will
improve over time, in part due to the introduction of
newer and more accurate coding systems such as ICD-9-
CM-2007.
In conclusion, our study underscores the importance of
the primary role that nephrologists have in the education
of healthcare professionals, particularly primary care pro-
viders [55,56]. This will help to call attention to CKD, a
pathology whose impact on public health is enormous
and is rapidly rising.
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